loading page

COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions.
  • +5
  • David Back,
  • Catia Marzolini,
  • Catherine Hodge,
  • Fiona Marra,
  • Alison Boyle,
  • Sara Gibbons,
  • David M. Burger,
  • Saye Khoo
David Back
University of Liverpool Faculty of Health and Life Sciences
Author Profile
Catia Marzolini
Author Profile
Catherine Hodge
Author Profile
Fiona Marra
University of Liverpool Faculty of Health and Life Sciences
Author Profile
Alison Boyle
Author Profile
Sara Gibbons
University of Liverpool Faculty of Health and Life Sciences
Author Profile
David M. Burger
Radboud university medical center
Author Profile
Saye Khoo
University of Liverpool Faculty of Health and Life Sciences
Author Profile

Peer review status:Published

29 Apr 2020Submitted to British Journal of Clinical Pharmacology
30 Apr 2020Assigned to Editor
30 Apr 2020Submission Checks Completed
04 May 2020Editorial Decision: Accept
Published in British Journal of Clinical Pharmacology. 10.1111/bcp.14358

Abstract

In a recent issue of Br J Clin Pharmacol Smith et al1 published an outstanding commentary titled ‘Dosing will be a key success factor in repurposing antivirals for Covid-19’. They highlighted that the success in our repurposing efforts will be dependent on ‘getting the dose right’ for drugs which have been developed for different indications and stressed some of the unique challenges of treating this particular disease. They pointed the reader to lopinavir/ritonavir (LPV/r) as an example of a repurposed antiviral and the limited experience of this drug regimen (and other treatments) in the elderly population with comorbidities – ie those most at risk from Covid-19. It is on the issue of comorbidities, polypharmacy and drug-drug interactions (DDIs) that we wish to comment.